MedTrace Logo

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

NCT05062278 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-10-18

No results posted yet for this study

Summary

Vinblastine can leukoreduce patients with newly diagnosed AML and hyperleukocytosis but clinical trials are lacking.

Conditions

  • AML
  • Hyperleukocytosis

Interventions

DRUG

Vinblastine

Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).

DRUG

Hydroxyurea capsules

Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • David Gomez · Universidad Autonoma de Nuevo Leon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2025-07-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062278 on ClinicalTrials.gov